Articles, guides, and regulatory updates from our community.
New research suggests SS-31 (Elamipretide) may modulate alpha-synuclein aggregation and restore mitochondrial function in Parkinson's-related models.
By Peptide Association Research Team
New research explores repurposed drugs targeting Alzheimer's disease pathways. Learn what the latest evidence suggests about emerging therapeutic strategies.
By Peptide Association Research Team
New research suggests elamipretide (SS-31) may support recovery after spinal cord injury by protecting mitochondria and reducing cell death. Learn what the study found.
By Peptide Association Research Team
New research reveals how NAD+ may help restore brain function in Alzheimer's disease through REST protein modulation. Study findings and clinical implications.
By Peptide Association Research Team